AMSTERDAM, January 22 /PRNewswire/ -- Avantium Technologies announces the launch of a new system to study crystallization processes for the pharmaceutical industry. The system will be marketed under the name Crystalline.
The Crystalline has been designed to address the need in the pharma industry to learn as much as possible about a drug candidate early in the development cycle.
"Avantium is proud to launch its next system in crystallization research. The Crystalline follows the success of our Crystal16TM, that is used by all Top 20 pharma companies", commented Tom van Aken, CEO of Avantium. "We are excited about the positive feedback of our customers to the new features and advanced analytics of our new Crystalline."
The Crystalline enables easy access for scientists to valuable information on drug candidates, when only a limited amount of sample is available. Bench chemists can use in situ analytics, on a milliliter scale: visualization through the vial (on-board camera's and particle analysis software) and real time Raman spectroscopy.
Crystalline is a small volume parallel crystallizer with overhead stirring and refluxing capabilities. The system and software have been designed by scientists who perform crystallization experiments on a daily basis, making it easy to program and operate.
The system can be customized, combining turbidity information with a parallel particle viewer or with real time Raman capabilities, shedding light on chemical reactions, crystallization processes, polymorph conversions, salt or co-crystal formation.
Avantium is a leading technology company in the area of advanced
high-throughput R&D operating in the energy, chemicals and pharmaceutical
industries. The company develops products and processes in the area of
biofuels, bio-based chemicals and novel crystal forms of existing drugs by
|SOURCE Avantium Technologies B.V.|
Copyright©2009 PR Newswire.
All rights reserved